Hepatitis C virus infection and vasculitis: Implications of antiviral and immunosuppressive therapies

Arthritis and Rheumatism

Volumn 46, Issue 3, 2002, Pages 585-597

  Vassilopoulos, Dimitrios ^a   Calabrese, Leonard H ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; AZATHIOPRINE; CHLORAMBUCIL; CLADRIBINE; COMPLEMENTARY DNA; CORTICOSTEROID; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHYLPREDNISOLONE; POLYPROTEIN; PREDNISONE; REBETRON; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; RITUXIMAB; RNA; VIRUS RNA;

BLOOD TRANSFUSION; CLINICAL FEATURE; CLINICAL TRIAL; CYTOPENIA; DEPRESSION; DNA LIBRARY; EPIDEMIC; FLAVIVIRUS; GASTROINTESTINAL SYMPTOM; GENETIC VARIABILITY; HEMOLYTIC ANEMIA; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; LONG TERM CARE; NOSE CONGESTION; PLASMA HALF LIFE; PLASMAPHERESIS; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; VASCULITIS; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PRACTICE GUIDELINES; VASCULITIS;

EID: 0036188310     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10107     Document Type: Review

References (92)

1. Virus-associated vasculitides: Clinical
2. Infections and systemic vasculitis
3. Epidemiology of hepatitis C
4. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease
5. Hepatitis C virus infection
6. Pathogenesis, natural history, treatment, and prevention of hepatitis C
7. Projecting future hepatitis C morbidity, mortality in the US, an awakening giant?
8. Clinical Medical Research Award: Hepatitis C virus and eliminating post-transfusion hepatitis
9. Replication of hepatitis C virus
10. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
11. Decay characteristics of HIV-1-infected compartments during combination therapy
12. The spectrum of extrahepatic manifestations in hepatitis C virus infection
13. Mixed cryoglobulinemia and other extrahepatic manifestations of hepatitis C virus infection
14. Mixed cryoglobulinemia in hepatitis C patients
15. Detection of occult low-grade B-cell non-Hodgkin's lymphoma in patients with chronic hepatitis C infection and mixed cryoglobulinemia
16. Extrahepatic manifestations associated with hepatitis C virus infection: A prospective multicenter study of 321 patients
17. Cryoglobulinemia in chronic liver diseases: Role of hepatitis C virus and liver damage
18. Extrahepatic manifestations of chronic hepatitis C
19. High prevalence of serum cryoglobulins in multitransfused hemophilic patients with chronic hepatitis C
20. Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C
21. Systemic manifestations and liver disease in patients with chronic hepatitis C and type II or III mixed cryoglobulinaemia
22. Cryoglobulinaemias: A multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease
23. The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection
24. Peripheral neuropathy in mixed cryoglobulinemia: Clinical and electrophysiologic investigations
25. Neurologic complications associated with hepatitis C virus infection
26. Peripheral neuropathy associated with essential mixed cryoglobulinaemia: A role for hepatitis C virus infection?
27. Nonsystemic vasculitic mononeuropathy multiplex, cryoglobulinemia, and hepatitis C
28. Renal involvement in hepatitis C infection: Cryoglobulinemic glomerulonephritis
29. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis
30. Mixed cryoglobulinemia: Clinical aspects and long-term follow-up of 40 patients
31. Systemic vasculitis in patients with hepatitis C
32. Localization of hepatitis C virus in cutaneous vasculitic lesions in patients with type II cryoglobulinemia
33. Secondary and essential cryoglobulinemias: Frequency, nosological classification, and long-term follow-up
34. Type II essential mixed cryoglobulinaemia: Presentation, treatment and outcome in 13 patients
35. Complex management issues: Management of HCV in the atypical patient
36. Therapy of chronic hepatitis C
37. Peginterferon alfa-2a in patients with chronic hepatitis C
38. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
39. Cryoglobulinemia
40. Treatment of idiopathic mixed cryoglobulinemia with alpha interferon
41. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: A long-term, randomized, controlled study
42. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus
43. Interferon-alpha in mixed cryoglobulinemia patients: A randomized, crossover-controlled trial
44. Effects of two different alpha-interferon regimens on clinical and virological findings in mixed cryoglobulinemia
45. Interferon in the treatment of mixed cryoglobulinemia
46. Effects of long-term course of alpha-interferon in patients with chronic hepatitis C associated to mixed cryoglobulinaemia
47. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection
48. Interferon therapy in HCV-positive mixed cryoglobulinaemia: Viral and host factors contributing to efficacy of the therapy
49. Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia
50. Response to interferon a treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus
51. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interfero-nalpha
52. Interferon-alpha treatment of hepatitis C virus-associated mixed cryoglobulinemia
53. Mixed cryoglobulinaemia associated with hepatitis C virus infection: A predictor factor for treatment with interferon?
54. Interferon and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia
55. Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies
56. Short-term prednisone therapy affects amino-transferase activity and hepatitis C virus RNA levels in chronic hepatitis C
57. Hepatitis C viremia in chronic liver disease: Relationship to interferon-alpha or corticosteroid treatment
58. Steroid therapy of chronic hepatitis: Characteristics associated with response in anti-hepatitis C virus-positive and -negative patients
59. Selected drug complications and treatment conflicts in the presence of coexistent diseases
60. Impact of hepatitis B and C virus on kidney transplantation outcome
61. Clinical outcome of HCV infection after renal transplantation
62. Hepatitis C viral infection in the immuno-suppressed patient
63. Hepatitis viruses and hematopoietic cell transplantation: A guide to patient and donor management
64. Azathioprine hepatitis in kidney transplant recipients: A predisposing role of chronic viral hepatitis
65. Increased susceptibility for CsA-induced hepatotoxicity in kidney graft recipients with chronic viral hepatitis C
66. Glomerulonephritis in mixed cryoglobulinaemia: What treatment?
67. Use of plasmapheresis and partial plasma exchange in the management of patients with cryoglobulinemia
68. Plasmapheresis with return of cryoglobulin-depleted autologous plasma (cryoglobulinpheresis) in cryoglobulinemia
69. The effect of combination therapy (steroids, immunosuppressives, and plasmapheresis) on 5 mixed cryoglobulinemia patients with renal, neurologic, and vascular involvement
70. Plasma exchange in the treatment of essential mixed cryoglobulinemia nephropathy: Long-term follow up
71. Treatment of the renal involvement in mixed cryoglobulinemia with prolonged plasma exchange
72. Long-term plasma exchange: Analysis of indications, outcome and side effects
73. Ribavirin therapy for cryoglobulinemia and thrombocytopenia associated with hepatitis C virus infection
74. Ribavirin in hepatitis C related cryoglobulinemia
75. Response to high-dose interferon-alpha after failure of standard therapy in MPGN associated with hepatitis C virus infection
76. Prolonged, complete remission after 2-chlorodeoxyadenosine therapy in a patient with refractory essential mixed cryoglobulinemia
77. Splenectomy may improve the glomerulopathy of type II mixed cryoglobulinemia
78. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection
79. Etanercept and hepatitis C
80. Rituximab for the treatment of type II mixed cryoglobulinemia
81. Rituximab as first-line systemic therapy for patients with low-grade lymphoma
82. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders
83. Disease assessment and management of the vasculitides
84. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis
85. Birmingham vasculitis activity score, disease extent index and complement factor C3c reflect disease activity best in hepatitis C virus-associated cryoglobulinemic vasculitis
86. Cryoglobulinemic vasculitis
87. Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon therapy in chronic hepatitis C
88. Interferon-a may exacerbate cryoglobulinemia-related ischemic manifestations: An adverse effect potentially related to its anti-angiogenic activity
89. Acute exacerbation of vasculitis during interferon-alpha therapy for hepatitis C-associated cryoglobulinaemia
90. Dramatic worsening of hepatitis C virus-related cryoglobulinemia subsequent to treatment with interferon alfa
91. Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy
92. Therapy for cryoglobulinemia secondary to hepatitis C virus: The need for tailored protocols and multiclinic studies